Sionna Therapeutics, Inc.
SION
NASDAQ
Healthcare
$43.99
+5.64%gain today
Market position
Market cap rank
#2104
of 2,614
1-day
+5.64%
1-month
+20.59%
6-month
+6.93%
YTD
+12.19%
1-year
+110.78%
5-year
—
Key figures
Market cap
$1.99B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-21.9
FY 2025
EPS
-$1.88
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
0.00%
FY 2025
Operating margin
0.00%
FY 2025
Net margin
0.00%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$1.59B
FY 2025
EV / EBITDA
-21.36
FY 2025
EV / Sales
0.00
FY 2025
Price / book
5.36
FY 2025
Price / sales
0.00
FY 2025
Earnings yield
-4.58%
FY 2025
FCF yield
-4.06%
FY 2025
Debt / equity
0.03
FY 2025
Current ratio
20.61
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$0
Gross profit
$-647K
Operating income
$-88.98M
EBITDA
$-74.62M
Net income
$-75.27M
Diluted EPS
-$1.88
Shares outstanding
39,962,163
Trading
Open
$41.04
Previous close
$41.64
Day range
$41.04 – $44.01
52-week range
$16.38 – $48.45
50-day avg
$39.86
200-day avg
$38.04
Volume
321,045
Avg volume
426,388
Beta
1.32
Price history
+110.78% over 1Y
Compare with peers
About Sionna Therapeutics, Inc.
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
Visit websiteCompany info
CEO
Michael Cloonan
IPO date
Feb 7, 2025
Headquarters
Waltham, MA, US
Country
US
Fundamentals are annual. Figures labeled with their fiscal year.
